ALNYLAM PHARMACEUTICALS INC (DUL.DE) Stock Earnings & Estimates
Europe - Frankfurt Stock Exchange - FRA:DUL - US02043Q1076 - Common Stock
301.3 EUR
-9.3 (-2.99%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.037B 22.87% | 1.828B 76.24% | 2.248B 22.97% | 3.831B 70.40% | 5.484B 43.15% | 7.002B 27.68% | 8.239B 17.67% | 10.155B 23.26% | 11.644B 14.66% | 12.053B 3.51% | 12.843B 6.55% | 13.625B 6.09% | |
| EBITDA YoY % growth | -740.6M -12.03% | -228.121M 69.20% | -120.215M 47.30% | 561.68M 567.23% | 1.294B 130.38% | 2.13B 64.61% | 6.144B 188.45% | 8.785B 42.99% | 10.297B 17.21% | N/A | N/A | N/A | |
| EBIT YoY % growth | -785.1M -10.78% | -282.175M 64.06% | -176.885M 37.31% | 500.47M 382.94% | 1.051B 110.00% | 1.954B 85.92% | 3.16B 61.72% | 4.231B 33.89% | 5.46B 29.05% | 6.166B 12.93% | 7.002B 13.56% | 7.645B 9.18% | |
| Operating Margin | -75.68% | -15.43% | -7.87% | 13.06% | 19.16% | 27.91% | 38.35% | 41.66% | 46.89% | 51.16% | 54.52% | 56.11% | |
| EPS YoY % growth | -8.66 -21.63% | -3.56 58.89% | -2.17 39.04% | 2.38 209.79% | 7.16 200.61% | 13.60 89.90% | 21.81 60.36% | 29.23 33.99% | 32.11 9.87% | 35.12 9.36% | 39.42 12.25% | 44.26 12.29% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.17 280.28% | 1.49 437.82% | 1.74 440.73% | 2.00 -5.30% | 2.11 80.01% | 1.95 31.07% | 2.25 29.72% | 2.59 29.65% | 3.01 42.65% |
| Revenue Q2Q % growth | 1.204B 102.98% | 1.235B 107.85% | 1.354B 75.01% | 1.454B 16.41% | 1.548B 28.57% | 1.484B 20.16% | 1.574B 16.25% | 1.673B 15.06% | 1.788B 15.50% |
| EBITDA Q2Q % growth | 142.52M 393.92% | 277.81M 755.27% | 351.06M 2,789.38% | 457.21M 11.48% | 835.99M 486.58% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 193.4M 283.91% | 268.35M 1,384.48% | 315.72M 2,049.01% | 360.16M -2.13% | 347.68M 79.77% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 2.11 342.53% | 0.76 | 1.35 | 177.15% |
| Q2 2025 Q2Q % growth | -0.51 -292.31% | -0.73 | 0.22 | 30.60% |
| Q1 2025 Q2Q % growth | -0.44 15.38% | -1.03 | 0.59 | 57.21% |
| Q4 2024 Q2Q % growth | -0.65 40.91% | -0.64 | -0.01 | -2.21% |
| Q3 2024 Q2Q % growth | -0.87 -175.65% | -0.91 | 0.04 | 4.00% |
| Q2 2024 Q2Q % growth | -0.13 94.12% | -1.10 | 0.97 | 88.19% |
| Q1 2024 Q2Q % growth | -0.52 62.86% | -1.21 | 0.69 | 56.90% |
| Q4 2023 Q2Q % growth | -1.10 34.52% | -1.35 | 0.25 | 18.47% |
| Q3 2023 Q2Q % growth | 1.15 142.75% | -1.36 | 2.51 | 184.40% |
| Q2 2023 Q2Q % growth | -2.21 3.49% | -1.40 | -0.81 | -58.30% |
| Q1 2023 Q2Q % growth | -1.40 30.00% | -1.80 | 0.40 | 22.24% |
| Q4 2022 Q2Q % growth | -1.68 22.22% | -1.91 | 0.23 | 12.09% |
| Q3 2022 Q2Q % growth | -2.69 -64.02% | -1.78 | -0.91 | -51.47% |
| Q2 2022 Q2Q % growth | -2.29 -42.24% | -1.66 | -0.63 | -37.75% |
| Q1 2022 Q2Q % growth | -2.00 -16.96% | -1.88 | -0.12 | -6.57% |
| Q4 2021 Q2Q % growth | -2.16 -3.35% | -1.57 | -0.59 | -37.46% |
| Q3 2021 Q2Q % growth | -1.64 24.77% | -1.60 | -0.04 | -2.56% |
| Q2 2021 Q2Q % growth | -1.61 -3.21% | -1.65 | 0.04 | 2.16% |
| Q1 2021 Q2Q % growth | -1.71 6.56% | -1.76 | 0.05 | 3.03% |
| Q4 2020 Q2Q % growth | -2.09 | -1.74 | -0.35 | -19.89% |
| Q3 2020 Q2Q % growth | -2.18 | -1.67 | -0.51 | -30.49% |
| Q2 2020 Q2Q % growth | -1.56 | -1.75 | 0.19 | 10.74% |
| Q1 2020 Q2Q % growth | -1.83 | -1.92 | 0.09 | 4.60% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 1.249B 149.35% | 997.35M | 251.676M | 25.23% |
| Q2 2025 Q2Q % growth | 773.689M 17.26% | 669.92M | 103.769M | 15.49% |
| Q1 2025 Q2Q % growth | 594.189M 20.20% | 597.54M | -3.351M | -0.56% |
| Q4 2024 Q2Q % growth | 593.166M 34.90% | 595.47M | -2.304M | -0.39% |
| Q3 2024 Q2Q % growth | 500.919M -33.26% | 543.76M | -42.841M | -7.88% |
| Q2 2024 Q2Q % growth | 659.825M 106.97% | 452.99M | 206.835M | 45.66% |
| Q1 2024 Q2Q % growth | 494.333M 54.82% | 435.88M | 58.453M | 13.41% |
| Q4 2023 Q2Q % growth | 439.718M 31.26% | 451.75M | -12.032M | -2.66% |
| Q3 2023 Q2Q % growth | 750.5M 183.96% | 391.21M | 359.29M | 91.84% |
| Q2 2023 Q2Q % growth | 318.8M 41.81% | 357.52M | -38.72M | -10.83% |
| Q1 2023 Q2Q % growth | 319.3M 49.70% | 318.5M | 800K | 0.25% |
| Q4 2022 Q2Q % growth | 335M 29.59% | 319.4M | 15.6M | 4.88% |
| Q3 2022 Q2Q % growth | 264.3M 40.88% | 297.59M | -33.29M | -11.19% |
| Q2 2022 Q2Q % growth | 224.8M 1.90% | 261M | -36.2M | -13.87% |
| Q1 2022 Q2Q % growth | 213.3M 20.10% | 248.24M | -34.94M | -14.08% |
| Q4 2021 Q2Q % growth | 258.5M 58.01% | 238.3M | 20.2M | 8.48% |
| Q3 2021 Q2Q % growth | 187.6M 49.01% | 223.07M | -35.47M | -15.90% |
| Q2 2021 Q2Q % growth | 220.6M 112.12% | 196.66M | 23.94M | 12.17% |
| Q1 2021 Q2Q % growth | 177.6M 78.49% | 172.11M | 5.49M | 3.19% |
| Q4 2020 Q2Q % growth | 163.6M | 149.74M | 13.86M | 9.26% |
| Q3 2020 Q2Q % growth | 125.9M | 123.17M | 2.73M | 2.22% |
| Q2 2020 Q2Q % growth | 104M | 101.47M | 2.53M | 2.49% |
| Q1 2020 Q2Q % growth | 99.5M | 93.552M | 5.948M | 6.36% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -5.97% | N/A | 27.26% | N/A |
| Revenue | 0.58% | N/A | 0.21% | N/A |